30 studies found for:    gsk | systemic lupus erythematosus
Show Display Options
Rank Status Study
1 Terminated An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184
Condition: Systemic Lupus Erythematosus
Interventions: Drug: GSK2586184 50 mg;   Drug: GSK2586184 100 mg;   Drug: GSK2586184 200 mg;   Drug: GSK2586184 400 mg;   Drug: Placebo
2 Completed Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Intervention: Drug: GSK1550188 1mg/kg or 10mg/kg
3 Recruiting GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Belimumab;   Drug: Placebo
4 Completed A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184
Condition: Systemic Lupus Erythematosus
Interventions: Drug: GSK2586184 standard formulation;   Drug: Simvastatin;   Drug: Rosuvastatin;   Drug: GSK2586184 new formulation
5 Completed A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender
Condition: Systemic Lupus Erythematosus
Interventions: Drug: GSK2586184 800mg single and repeat dose;   Drug: Placebo-to-match GSK2586184;   Other: GSK2586184 single dose taken with food;   Other: GSK2586184 single dose taken without food
6 Completed Japanese phase1 Study of Belimumab (IV vs SC)
Condition: Systemic Lupus Erythematosus
Interventions: Drug: GSK1550188 IV;   Drug: GSK1550188 SC
7 Recruiting Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
Condition: Systemic Lupus Erythematosus
Interventions: Biological: BENLYSTA;   Other: SLE treatment
8 Recruiting Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
9 Recruiting A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Belimumab plus Early Vaccination;   Biological: Belimumab plus Late Vaccination
10 Recruiting Belimumab Assessment of Safety in SLE
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Other: Standard therapy
11 Recruiting Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
Condition: Systemic Lupus Erythematosus
Interventions: Drug: belimumab 10mg/kg;   Other: placebo
12 Recruiting BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Belimumab
13 Recruiting Belimumab (BENLYSTA®) Pregnancy Registry
Condition: Systemic Lupus Erythematosus
Intervention: Drug: belimumab
14 Recruiting Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients.
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Belimumab
15 Active, not recruiting A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 200 mg SC plus standard therapy;   Drug: Standard therapy
16 Recruiting A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector
Condition: Systemic Lupus Erythematosus
Intervention: Device: Belimumab autoinjector
17 Active, not recruiting A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02
Condition: Systemic Lupus Erythematosus
Intervention: Biological: Belimumab
18 Active, not recruiting A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057
Condition: Systemic Lupus Erythematosus
Intervention: Drug: belimumab
19 Active, not recruiting A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Belimumab 1 mg/kg;   Biological: Belimumab 10 mg/kg
20 Completed A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Belimumab 200 mg/mL

Previous Page Studies Shown (1-20) Next Page (21-30) Show next page of results
Indicates status has not been verified in more than two years